GKOS241220P80000
- 0.00
- 0.000.00%
Glaukos Newsroom
BTIG Maintains Buy on Glaukos, Raises Price Target to $149
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $149
The Three-year Returns Have Been Splendid for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Glaukos Revolutionizes Glaucoma Treatment With IDose TR Approval
Glaukos Announces Participation in Upcoming Investor Conferences
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating
Glaukos Price Target Raised to $145 From $135 at Wells Fargo
Glaukos Third Quarter 2024 Earnings: Beats Expectations
Mizuho Securities Maintains Glaukos(GKOS.US) With Hold Rating
Uncertain Growth and Reimbursement Challenges Keep Glaukos's IDose at Hold Rating
Glaukos | 10-Q: Q3 2024 Earnings Report
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Glaukos Is Maintained at Overweight by Wells Fargo
Glaukos Analyst Ratings
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $140 to $149
Glaukos (GKOS) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and Vertex Pharmaceuticals (VRTX)
Glaukos' Strong Q3 2024 Performance and IDose's Growth Propel Buy Rating